Patient characteristics
| . | ND . | AD . | P . |
|---|---|---|---|
| Plasma studies | |||
| Patients, n | 18 | 40 | |
| Age, mean (SD), y | 66.00 (4.80) | 67.03 (5.93) | n.s. |
| Male, % | 47 | 51 | n.s. |
| BMI, mean (SD), kg/m2 | 28.76 (6.79) | 27.61 (6.45) | n.s. |
| MMSE score, mean (SD) | 29.71 (0.47) | 20.95 (3.78) | <.001 |
| APOE status, E4 carrier, % | 22 (4/18) | 59 (23/39) | |
| CSF studies | |||
| Patients, n | 15 | 33 | |
| CSF NF-L, mean (SD), pg/mL | 1287.41 (423.17) | 2505.93 (1337.56) | <.001 |
| CSF Aβ38, mean (SD), pg/mL | 2236.76 (1144.15) | 1762.89 (729.68) | n.s. |
| CSF Aβ40, mean (SD), pg/mL | 5079.83 (3369.65) | 4560.18 (1831.38) | n.s. |
| CSF Aβ42, mean (SD), pg/mL | 423.10 (278.97) | 249.49 (148.70) | <.01 |
| CSF Aβ40/42 ratio, mean (SD) | 13.16 (5.90) | 20.73 (7.44) | <.001 |
| . | ND . | AD . | P . |
|---|---|---|---|
| Plasma studies | |||
| Patients, n | 18 | 40 | |
| Age, mean (SD), y | 66.00 (4.80) | 67.03 (5.93) | n.s. |
| Male, % | 47 | 51 | n.s. |
| BMI, mean (SD), kg/m2 | 28.76 (6.79) | 27.61 (6.45) | n.s. |
| MMSE score, mean (SD) | 29.71 (0.47) | 20.95 (3.78) | <.001 |
| APOE status, E4 carrier, % | 22 (4/18) | 59 (23/39) | |
| CSF studies | |||
| Patients, n | 15 | 33 | |
| CSF NF-L, mean (SD), pg/mL | 1287.41 (423.17) | 2505.93 (1337.56) | <.001 |
| CSF Aβ38, mean (SD), pg/mL | 2236.76 (1144.15) | 1762.89 (729.68) | n.s. |
| CSF Aβ40, mean (SD), pg/mL | 5079.83 (3369.65) | 4560.18 (1831.38) | n.s. |
| CSF Aβ42, mean (SD), pg/mL | 423.10 (278.97) | 249.49 (148.70) | <.01 |
| CSF Aβ40/42 ratio, mean (SD) | 13.16 (5.90) | 20.73 (7.44) | <.001 |
APOE, apolipoprotein E; BMI, body mass index; n.s., not significant; SD, standard deviation.